Tirzepatide (Zepbound)
Canadian Journal of Health Technologies · 14.10.2026 · 6 (10)
DOI: 10.51731/cjht.2026.1538 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 14.10.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses tirzepatide (Zepbound), 2.5mg/0.6 mL, 5 mg/0.6 mL, 7.5 mg/0.6 mL, 10 mg/0.6 mL, 12.5 mg/0.6 mL, and 15 mg/0.6 mL, solution in a multidose prefilled pen for subcutaneous use. Indication: For once-weekly administration for chronic weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity, in adults with an initial BMI of: 30 kg/m2 or greater (obesity) or 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least 1 weight-related comorbid condition (e.g., hypertension, dyslipidemia, prediabetes, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease).
Zitieren
APA
CDA-AMC (2026). Tirzepatide (Zepbound). Canadian Journal of Health Technologies, 6(10). https://doi.org/10.51731/cjht.2026.1538
Vancouver
CDA-AMC. Tirzepatide (Zepbound). Canadian Journal of Health Technologies. 2026;6(10). doi:10.51731/cjht.2026.1538
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Tirzepatide (Zepbound)},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {10},
doi = {10.51731/cjht.2026.1538}
}
EUVIMED